Study partners should be required in preclinical Alzheimer's disease trials.
Joshua D GrillJason KarlawishPublished in: Alzheimer's research & therapy (2017)
Preclinical AD will represent a new model of care, in which persons with no symptoms are informed of probable cognitive decline and eventual dementia. The rationale for early diagnosis in symptomatic AD is equally applicable in preclinical AD-to minimize risk, maximize quality of life, and ensure optimal planning and communication. Family members and other sources of support will likely be essential to the goals of this new model of care for preclinical AD patients and trials must instruct this clinical practice.
Keyphrases
- depressive symptoms
- cognitive decline
- mild cognitive impairment
- cell therapy
- healthcare
- clinical practice
- palliative care
- end stage renal disease
- ejection fraction
- quality improvement
- clinical trial
- cognitive impairment
- patient reported outcomes
- affordable care act
- chronic pain
- hiv infected
- patient reported
- breast cancer risk